Skip to main content

Table 2 Demographic and clinical characteristics at admission

From: Continuous venovenous hemodiafiltration versus standard medical therapy for the prevention of rhabdomyolysis-induced acute kidney injury: a retrospective cohort study

Variable

CVVHDF + SMT group (n = 9)

SMT group

(n = 9)

P value

Sex

  

0.730

Male

8 (88.89%)

7 (77.78%)

 

Female

1 (11.11%)

2 (22.22%)

 

Age (years)

  

0.546

10–19

2 (22.22%)

2 (22.22%)

 

20–29

2 (22.22%)

1 (11.11%)

 

30–39

0 (0.00%)

2 (22.22%)

 

40–49

1 (11.11%)

1 (11.11%)

 

50–59

0 (0.00%)

1 (11.11%)

 

60–69

1 (11.11%)

0 (0.00%)

 

≥ 70

3 (33.33%)

2 (22.22%)

 

Causes

  

0.502

Crush injury

4 (44.44%)

3 (33.33%)

 

Strenuous exercise

2 (22.22%)

3 (33.33%)

 

Heat stroke

1 (22.22%)

0 (0.00%)

 

Drugs

1 (11.11%)

3 (33.33%)

 

CO poisoning

1 (11.11%)

0 (0.00%)

 

Clinical symptoms

   

Myohemoglobinuria

  

1.000

Yes

3 (33.33%)

3 (33.33%)

 

No

6 (66.67%)

6 (66.67%)

 

Muscular soreness

  

0.436

Yes

4 (44.44%)

7 (77.78%)

 

No

5 (55.56%)

2 (22.22%)

 

Medical history

   

Hypertension history

  

1.000

Yes

1 (11.11%)

2 (22.22%)

 

No

8 (88.89%)

7 (77.78%)

 

Diabetes history

  

0.730

Yes

1 (11.11%)

0 (0.00%)

 

No

8 (88.89%)

9 (100%)

 

Heart disease history

  

0.730

Yes

0 (0.00%)

0 (0.00%)

 

No

9 (100%)

9 (100%)

 

Laboratory indicators

  

Mb (ng/mL)

3000 (2778.5–3000.0)

2921 (805.7–3000.0)

0.796

CK (U/L)

15,133 (8881–123,845.5)

17,155 (8854.5–105,738.5)

0.931

CK-MB (U/L)

639.8 (149.4–1837.1)

601.3 (174.9–1859.3)

0.796

Cr (µmol/L)

96.889 ± 31.442

67.556 ± 9.002

0.139

BUN (mmol/L)

9.344 ± 5.110

5.967 ± 2.588

0.063

LDH (U/L)

875 (596.5–3773.5)

616 (550–2664.5)

0.222

ALT (U/L)

85 (55–356.3)

109.5 (82–268.2)

0.931

AST (U/L)

243 (169–1222.0)

300 (199–916.0)

0.931

WBC (109/L)

15.898 ± 7.391

12.567 ± 5.227

0.147

HGB (g/L)

155.22 ± 16.581

151.22 ± 7.563

0.690

HCT (%)

45.6 (41.5–52.8)

43.5 (41.6–46.4)

0.796

CO2-cp (mmol/L)

20.433 ± 6.464

25.90 ± 4.348

0.153

Urine (pH)

5.5 (5.3–5.8)

6.5 (5.5–7.3)

0.063

d-Dimer (µg/mL)

1.77 (0.5–4.2)

0.6 (0.2–0.8)

0.136

CTnT (ng/mL)

0.09 (0.01–0.3)

0.003 (0.003–0.05)

0.063

Ca2+ (mmol/L)

2.108 ± 0.167

2.103 ± 0.169

0.345

 K+ (mmol/L)

4.4 (4.2–4.5)

4.3 (2.8–4.5)

0.796

Na+ (mmol/L)

138.400 ± 4.410

138.330 ± 4.500

0.919

AG (mmol/L)

16.967 ± 11.507

11.100 ± 2.197

0.177

  1. CVVHDF + SMT group, received continuous venovenous hemodiafiltration (CVVHDF) combined with standard medical therapy (SMT); SMT group, received SMT only. Values are presented as mean ± standard deviation, median (25–75% interquartile range), or number (percentage)
  2. CO, carbon monoxide; Mb, myoglobin; CK, creatine kinase; CK-MB, creatine kinase-MB; Cr, creatinine; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; WBC, white blood cell; HGB, hemoglobin; HCT, hematocrit; CO2-cp, carbon dioxide combining power; CTnT, cardiac troponin T; and AG, anion gap